Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 17/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
| ▸ | LIPE | Q05469 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1677054 | 0.87 | EPHX2 (0.52) | EPHX2EPHX1FAAHCCR2 | |
| SCHEMBL1677171 | 0.79 | CCR2 (0.57) | EPHX2EPHX1FAAHCCR2LIPE | |
| SCHEMBL1677030 | 0.79 | EPHX2 (0.53) | EPHX2EPHX1FAAHCCR2LIPE | |
| SCHEMBL1677062 | 0.79 | MGLL (0.52) | EPHX2EPHX1FAAH | |
| SCHEMBL1677174 | 0.78 | EPHX2 (0.63) | EPHX2EPHX1LIPE | |
| SCHEMBL1677020 | 0.75 | EPHX2 (0.58) | EPHX2EPHX1FAAHLIPE | |
| SCHEMBL1677021 | 0.75 | EPHX2 (0.58) | EPHX2EPHX1FAAHLIPE | |
| SCHEMBL1677205 | 0.73 | EPHX2 (0.59) | EPHX2EPHX1FAAHLIPE | |
| SCHEMBL2233568 | 0.71 | EPHX2 (0.46) | EPHX2EPHX1 | |
| SCHEMBL12217997 | 0.71 | EPHX2 (0.86) | EPHX2EPHX1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518934-B2 | Oxycarbamoyl compounds and the use thereof | SHONOGI & CO., LTD. (JP) | 2013-08-27 | — | — | US | disclosed |
| EP-2346820-B1 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO (JP) | 2013-02-13 | — | — | EP | disclosed |
| US-20110098276-A1 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2011-04-28 | — | — | US | disclosed |
| US-20110098276-A1 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098276-A1 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF | CACNA1B, ORAI1, CACNA1I | EPHX2 1203/4885EPHX1 1083/4885FAAH 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.